BioSpace News Archive

Access Vascular, Inc. announced it has been named a winner in the 2022 BIG Innovation Awards presented by the Business Intelligence Group.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today reported progress across its pipeline of targeted therapeutics spanning its RAS(ON) Inhibitor and RAS Companion Inhibitor portfolios.

Minerva Surgical, Inc., a medical device company that has established a broad product line of commercially available, minimally invasive medical devices that address the most common causes of abnormal uterine bleeding as alternatives to hysterectomy, reported preliminary unaudited fourth quarter and full year 2021 revenue expectations.

BeyondSpring Pharmaceuticals announced an organizational streamlining initiative focused on prioritizing the Company’s highest value business activities, extending its cash runway and preserving long-term sustainability.

Glaukos Corporation (NYSE: GKOS), today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.

Cigna Corporation, a global health service company, was named one of America’s Most JUST Companies, making this the third year that the organization has been recognized for its corporate citizenship.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that Dr. Dajun Yang, the company’s Chairman and CEO, delivered a presentation at the virtually-held 40th Annual J.P. Morgan Healthcare Conference.

ThermoGenesis Holdings, Inc., announced that the Company’s 2021 Annual Meeting of Stockholders will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST.

HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, today announced a major milestone in ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS) in Israel.

Catalyst OrthoScience Inc., a medical device company focused on the upper extremity orthopedics market, has named Carl O’Connell as president and chief executive officer effective immediately.